Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 129

    1.

    Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.

    Yan Y, Skliris GP, Penner C, Chooniedass-Kothari S, Cooper C, Nugent Z, Blanchard A, Watson PH, Myal Y, Murphy LC, Leygue E.

    Breast Cancer Res. 2009;11(5):R67. Epub .

    PMID:
    19740422
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    The steroid receptor RNA activator protein is expressed in breast tumor tissues.

    Chooniedass-Kothari S, Hamedani MK, Troup S, Hubé F, Leygue E.

    Int J Cancer. 2006 Feb 15;118(4):1054-9.

    PMID:
    16152589
    [PubMed - indexed for MEDLINE]
    3.

    DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.

    Ansems M, Hontelez S, Looman MW, Karthaus N, Bult P, Bonenkamp JJ, Jansen JH, Sweep FC, Span PN, Adema GJ.

    J Natl Cancer Inst. 2010 Jan 6;102(1):54-68. Epub 2009 Dec 14.

    PMID:
    20008677
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

    Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

    PMID:
    15330189
    [PubMed - indexed for MEDLINE]
    5.

    Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

    Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.

    PMID:
    18925950
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

    Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U.

    J Natl Cancer Inst. 1993 Jun 16;85(12):965-70.

    PMID:
    8496982
    [PubMed - indexed for MEDLINE]
    8.

    Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

    Breast Cancer Res Treat. 2009 Jul;116(1):131-43. Epub 2008 Jul 31.

    PMID:
    18668363
    [PubMed - indexed for MEDLINE]
    9.

    Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.

    Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL.

    Breast Cancer Res Treat. 2009 May;115(1):77-85. Epub 2008 Jun 3.

    PMID:
    18521745
    [PubMed - indexed for MEDLINE]
    10.

    Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.

    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.

    Acta Oncol. 2009;48(4):514-21.

    PMID:
    19107621
    [PubMed - indexed for MEDLINE]
    11.

    Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

    Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

    Cancer. 1994 Sep 1;74(5):1575-83.

    PMID:
    7914825
    [PubMed - indexed for MEDLINE]
    12.

    Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.

    Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF.

    Breast Cancer Res Treat. 2003 Mar;78(2):193-204.

    PMID:
    12725419
    [PubMed - indexed for MEDLINE]
    13.

    Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

    Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

    Clin Cancer Res. 2008 Mar 1;14(5):1368-76.

    PMID:
    18316557
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.

    Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.

    Breast Cancer Res Treat. 2009 Feb;113(3):457-66. Epub 2008 Mar 14.

    PMID:
    18340528
    [PubMed - indexed for MEDLINE]
    16.

    Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

    Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG.

    Mod Pathol. 2007 Jan;20(1):84-9. Epub 2006 Nov 24.

    PMID:
    17143263
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.

    Hu Z, Huang G, Sadanandam A, Gu S, Lenburg ME, Pai M, Bayani N, Blakely EA, Gray JW, Mao JH.

    Breast Cancer Res. 2010;12(2):R18. Epub 2010 Mar 8.

    PMID:
    20211017
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    18.

    Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.

    Azizun-Nisa, Bhurgri Y, Raza F, Kayani N.

    Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.

    PMID:
    19256737
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.

    Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO.

    Breast Cancer Res Treat. 2010 Jan;119(1):53-61. Epub 2009 Feb 10.

    PMID:
    19205877
    [PubMed - indexed for MEDLINE]
    20.

    Prognostic markers in triple-negative breast cancer.

    Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO.

    Cancer. 2007 Jan 1;109(1):25-32.

    PMID:
    17146782
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk